Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cobimetinib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cobimetinib + dexamethasone is an investigational combination regimen consisting of the MEK1/MEK2 inhibitor cobimetinib and the synthetic glucocorticoid dexamethasone. This combination is primarily being evaluated for the treatment of relapsed or refractory multiple myeloma, particularly in patients whose tumors harbor activating mutations in the MAPK pathway (such as KRAS, NRAS, or BRAF mutations). Cobimetinib selectively blocks MEK1 and MEK2 to inhibit downstream ERK phosphorylation and tumor cell proliferation, while dexamethasone provides synergistic anti-myeloma activity through glucocorticoid receptor activation. The regimen has been studied as a targeted lead-in therapy in the genomically-guided MyDRUG platform trial.
- Other names
- cobimetinib and dexamethasonecobimetinib/dexamethasone
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on cobimetinib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cobimetinib + dexamethasone.